Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's disease.
OBJECTIVE
Second malignancies have been reported among patients who were treated by radiation therapy or chemotherapy alone or in combination. Studies have implied an increased risk of breast cancer in women who received radiotherapy as part of their treatment for Hodgkin's disease. This review was performed to determine if there is an association between splenectomy and subsequent breast cancer.


METHODS
One hundred and thirty-six female patients with histologically proven Hodgkin's disease were seen in the Division of Radiation Oncology between 1962 and 1985. All patients received mantle or mediastinal irradiation as part of their therapy. The risk of breast cancer was assessed and multiple linear regression analysis was performed on the following variables: patient age, stage, dose and extent of radiation field, time after completing radiation therapy, splenectomy, and chemotherapy.


RESULTS
Breast cancer was observed in 11 of 74 splenectomized patients and in none of 62 patients not splenectomized. The mean follow-up was 13 years in splenectomized patients and 16 years, 7 months in nonsplenectomized patients. Nine patients developed invasive breast cancer and two developed ductal carcinoma in situ. Splenectomy was the only variable independently associated with an increased risk of breast cancer (p < 0.005) in multiple linear regression analysis; age, latency, and splenectomy considered together were also associated with an increased risk of breast cancer (p < 0.01).


CONCLUSIONS
Our data show an increased risk of breast cancer in splenectomized patients who had treatment for Hodgkin's disease. A multiinstitutional survey may better define the influence of splenectomy relative to developing breast cancer in patients treated for Hodgkin's disease. The risk of breast cancer should be considered when recommending staging laparotomy, and we recommend close follow-up examination including routine mammograms for female patients successfully treated for Hodgkin's disease.
Chung
C T
CT
Department of Radiation Oncology, State University of New York Health Science Center, Syracuse 13210, USA.
Bogart
J A
JA
Adams
J F
JF
Sagerman
R H
RH
Numann
P J
PJ
Tassiopoulos
A
A
Duggan
D B
DB
D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000209:etiology*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology*; D012306:Risk; D013156:Splenectomy / Q000009:adverse effects*; D016019:Survival Analysis